New England Enzyme Center
From Wikipedia, the free encyclopedia
The New England Enzyme Center (NEEC) was created at the Tufts University School of Medicine in Boston, Massachusetts in 1964 as a federally supported biochemical resource center.[1]
According to Doogab Yi, by the late 1970s NEEC had been transformed into "several commercial biotech companies."[1]
Roscoe O. Brady and his colleagues at National Institutes of Health (NIH) were almost ready for a clinical trial for an enzyme replacement therapy for Gaucher's disease that they had been working on for over a decade.[2]: 44 They could not purify the enzyme in large enough quantities.[2]: 44
"They contracted with Henry Blair, who had worked at NIH with Brady but left to form the New England Enzyme Center at Tufts University Medical School in Boston. Supported solely by contracts from Brady's lab, Blair set up a lab for large-scale purification and began collecting fresh placentas. In 1981, with NIH getting ready to move into larger clinical trials and biotechnology fever exploding around him, Blair privatized his venture. He launched Genzyme, with the NIH as its major source of revenue."
— Goozne 2005:44
Blair had started his career in the biotechnology industry working as a technician at Tufts medical school.[3][4] In 1978 Henry E. Blair, from the NEEC and a team of researchers including Peter G. Pentchev, Roscoe O. Brady, Daniel E. Britton and Susan H. Sorrell from the National Institutes of Health co-authored a paper in the PNAS isolating and comparing enzymes in search of a treatment for Gaucher disease.[5]
In 1981 venture capitalist Sheridan Snyder, Henry Blair and George M. Whitesides created the start-up Genzyme and continued to produce the enzymes for the NIH.[4][6] Genzyme's first office was an old clothing warehouse adjacent to Tufts Medical School.[3]
References
- 1 2 Doogab Yi (2009). "The scientific commons in the marketplace: the industrialization of biomedical materials at the New England Enzyme Center, 1963–1980". History and Technology. 25 (1): 69–87. doi:10.1080/07341510802618182. S2CID 144569826.
- 1 2 Merrill Goozne (October 2005), The $800 Million Pill: The Truth Behind the Cost of New Drugs, University of California Press, ISBN 9780520246706
- 1 2 Bruce Morgan (April 12, 2012), A Flair for the Business of Medicine: Genzyme founder Henry Blair started his career working as a technician at Tufts medical school, Tufts Now, retrieved July 17, 2015
- 1 2 Sara Calabro (1 March 2006), "Genzyme put patients first, and grew to become a multi-billion-dollar company. But empires don't survive on altruism", Pharmaceutical Executive, archived from the original on 7 February 2012, retrieved 18 July 2015
- ↑ Pentchev; Brady, RO; Blair, HE; Britton, DE; Sorrell, SH; et al. (August 1978). "Gaucher disease: Isolation and comparison of normal and mutant glucocerebrosidase from human spleen tissue". Proceedings of the National Academy of Sciences of the United States of America. 75 (8): 3970–3973. Bibcode:1978PNAS...75.3970P. doi:10.1073/pnas.75.8.3970. PMC 392911. PMID 29293.
- ↑ Michael Rosenwald (August 2010). "Can Nanotechnology Save Lives?". Smithsonian Magazine. Archived from the original on October 4, 2012. Retrieved August 16, 2012.